

## Losartan / Hydrochlorothiazide Formulation

Version 5.4      Revision Date: 16.10.2020      SDS Number: 17073-00016      Date of last issue: 23.03.2020  
Date of first issue: 30.09.2014

---

**SECTION 1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Losartan / Hydrochlorothiazide Formulation

**Manufacturer or supplier's details**

Company name of supplier : Organon & Co.  
Address : Avenida 16 de Septiembre No. 301  
Xaltocan - Xochimilco Mexico 16090  
Telephone : 52 55 57284444  
Emergency telephone : 215-631-6999  
E-mail address : EHSSTEWARD@organon.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification**

Acute toxicity (Oral) : Category 5  
Serious eye damage : Category 1  
Skin sensitization : Category 1  
Reproductive toxicity : Category 1B  
Effects on or via lactation  
Specific target organ toxicity : Category 1 (Kidney, Parathyroid gland)  
- repeated exposure  
Specific target organ toxicity : Category 2 (Blood, Cardio-vascular system, Stomach, Kidney)  
- repeated exposure (Oral)

**GHS label elements**

Hazard pictograms : 

Signal Word : Danger

Hazard Statements : H303 May be harmful if swallowed.  
H317 May cause an allergic skin reaction.  
H318 Causes serious eye damage.  
H360D May damage the unborn child.  
H362 May cause harm to breast-fed children.  
H372 Causes damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.  
H373 May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

## Losartan / Hydrochlorothiazide Formulation

Version 5.4      Revision Date: 16.10.2020      SDS Number: 17073-00016      Date of last issue: 23.03.2020  
Date of first issue: 30.09.2014

Precautionary Statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe dust.  
P263 Avoid contact during pregnancy and while nursing.  
P264 Wash skin thoroughly after handling.  
P270 Do not eat, drink or smoke when using this product.  
P272 Contaminated work clothing should not be allowed out of the workplace.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**  
P302 + P352 IF ON SKIN: Wash with plenty of water.  
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER or doctor/ physician.  
P312 Call a POISON CENTER or doctor/ physician if you feel unwell.  
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.  
P362 + P364 Take off contaminated clothing and wash it before reuse.

**Storage:**  
P405 Store locked up.

**Disposal:**  
P501 Dispose of contents/ container to an approved waste disposal plant.

**Other hazards**

Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

Substance / Mixture : Mixture

**Components**

| Chemical name       | CAS-No.     | Concentration (% w/w) |
|---------------------|-------------|-----------------------|
| Cellulose           | 9004-34-6   | >= 30 -< 50           |
| Losartan            | 124750-99-8 | >= 20 -< 30           |
| Starch              | 9005-25-8   | >= 10 -< 20           |
| Hydrochlorothiazide | 58-93-5     | >= 1 -< 5             |

**SECTION 4. FIRST AID MEASURES**

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical

## Losartan / Hydrochlorothiazide Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 23.03.2020  |
| 5.4     | 16.10.2020     | 17073-00016 | Date of first issue: 30.09.2014 |

---

- advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.  
If easy to do, remove contact lens, if worn.  
Get medical attention immediately.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May be harmful if swallowed.  
May cause an allergic skin reaction.  
Causes serious eye damage.  
May damage the unborn child.  
May cause harm to breast-fed children.  
Causes damage to organs through prolonged or repeated exposure.  
Contact with dust can cause mechanical irritation or drying of the skin.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

**SECTION 5. FIRE-FIGHTING MEASURES**

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Chlorine compounds  
Nitrogen oxides (NO<sub>x</sub>)  
Chlorine compounds  
Sulfur oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.

## Losartan / Hydrochlorothiazide Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 23.03.2020  |
| 5.4     | 16.10.2020     | 17073-00016 | Date of first issue: 30.09.2014 |

---

Special protective equipment for fire-fighters : Evacuate area.  
In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

---

**SECTION 6. ACCIDENTAL RELEASE MEASURES**

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

**SECTION 7. HANDLING AND STORAGE**

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling : Avoid contact during pregnancy and while nursing.  
Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Do not get in eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the

## Losartan / Hydrochlorothiazide Formulation

Version 5.4      Revision Date: 16.10.2020      SDS Number: 17073-00016      Date of last issue: 23.03.2020  
Date of first issue: 30.09.2014

- Hygiene measures : environment.  
: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.  
When using do not eat, drink or smoke.  
Contaminated work clothing should not be allowed out of the workplace.  
Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.
- Conditions for safe storage : Keep in properly labeled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents  
Organic peroxides  
Explosives  
Gases

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

| Components          | CAS-No.     | Value type (Form of exposure) | Control parameters / Permissible concentration | Basis             |
|---------------------|-------------|-------------------------------|--|-------------------|
| Cellulose           | 9004-34-6   | VLE-PPT                       | 10 mg/m <sup>3</sup>                           | NOM-010-STPS-2014 |
|                     |             | TWA                           | 10 mg/m <sup>3</sup>                           | ACGIH             |
| Losartan            | 124750-99-8 | TWA                           | 100 µg/m <sup>3</sup> (OEB 2)                  | Internal          |
| Starch              | 9005-25-8   | VLE-PPT                       | 10 mg/m <sup>3</sup>                           | NOM-010-STPS-2014 |
|                     |             | TWA                           | 10 mg/m <sup>3</sup>                           | ACGIH             |
| Hydrochlorothiazide | 58-93-5     | TWA                           | 100 µg/m <sup>3</sup> (OEB 2)                  | Internal          |

- Engineering measures** : Use feasible engineering controls to minimize exposure to compound.  
All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

**Personal protective equipment**

- Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
- Filter type : Particulates type
- Hand protection : Chemical-resistant gloves
- Material : Chemical-resistant gloves

## Losartan / Hydrochlorothiazide Formulation

Version 5.4      Revision Date: 16.10.2020      SDS Number: 17073-00016      Date of last issue: 23.03.2020  
Date of first issue: 30.09.2014

---

Eye protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

Skin and body protection : Work uniform or laboratory coat.

---

**SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES**

Appearance : powder

Color : yellow

Odor : odorless

Odor Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : Not applicable

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : Not applicable

Relative vapor density : Not applicable

Relative density : No data available

Density : No data available

Solubility(ies)  
Water solubility : No data available

Partition coefficient: n-octanol/water : Not applicable

Autoignition temperature : No data available

## Losartan / Hydrochlorothiazide Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 23.03.2020  |
| 5.4     | 16.10.2020     | 17073-00016 | Date of first issue: 30.09.2014 |

---

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle size : No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

---

**SECTION 11. TOXICOLOGICAL INFORMATION****Information on likely routes of exposure**

Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

May be harmful if swallowed.

**Product:**

Acute oral toxicity : Acute toxicity estimate: 2,201 mg/kg  
Method: Calculation method

**Components:****Cellulose:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

---

## Losartan / Hydrochlorothiazide Formulation

Version 5.4      Revision Date: 16.10.2020      SDS Number: 17073-00016      Date of last issue: 23.03.2020  
Date of first issue: 30.09.2014

---

**Losartan:**

Acute oral toxicity : LD50 (Mouse): 1,257 - 1,590 mg/kg  
LDLo (Rat): 200 mg/kg  
LDLo (Mouse): 400 mg/kg

**Starch:**

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

**Hydrochlorothiazide:**

Acute oral toxicity : LD50 (Rat): > 2,750 mg/kg  
LD50 (Mouse): > 2,830 mg/kg  
Acute toxicity (other routes of administration) : LD50 (Rat): 990 mg/kg  
Application Route: Intravenous  
LD50 (Mouse): 590 mg/kg  
Application Route: Intravenous

**Skin corrosion/irritation**

Not classified based on available information.

**Components:****Losartan:**

Species : Rabbit  
Result : Mild skin irritation

**Hydrochlorothiazide:**

Species : Rabbit  
Result : No skin irritation

**Serious eye damage/eye irritation**

Causes serious eye damage.

**Components:****Losartan:**

Species : Rabbit  
Result : Severe irritation

**Starch:**

Species : Rabbit  
Result : No eye irritation



## Losartan / Hydrochlorothiazide Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 23.03.2020  |
| 5.4     | 16.10.2020     | 17073-00016 | Date of first issue: 30.09.2014 |

---

**Hydrochlorothiazide:**

Species : Rabbit  
Result : Mild eye irritation

**Respiratory or skin sensitization****Skin sensitization**

May cause an allergic skin reaction.

**Respiratory sensitization**

Not classified based on available information.

**Components:****Losartan:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Assessment : Probability or evidence of skin sensitization in humans  
Result : positive

**Starch:**

Test Type : Maximization Test  
Routes of exposure : Skin contact  
Species : Guinea pig  
Result : negative

**Germ cell mutagenicity**

Not classified based on available information.

**Components:****Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative  
  
Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

**Losartan:**

Genotoxicity in vitro : Test Type: in vitro test  
Result: negative  
  
Test Type: In vitro mammalian cell gene mutation test  
Test system: Chinese hamster ovary cells  
Result: negative

## Losartan / Hydrochlorothiazide Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 23.03.2020  |
| 5.4     | 16.10.2020     | 17073-00016 | Date of first issue: 30.09.2014 |

---

Test Type: Alkaline elution assay

Result: negative

Test Type: Chromosomal aberration

Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration  
Result: negative

**Starch:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

**Hydrochlorothiazide:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosomal aberration

Test system: Chinese hamster ovary cells

Result: negative

Test Type: sister chromatid exchange assay

Test system: Chinese hamster ovary cells

Result: positive

Test Type: in vitro test

Test system: mouse lymphoma cells

Result: positive

Genotoxicity in vivo : Test Type: Chromosomal aberration  
Species: Chinese hamster  
Cell type: Bone marrow  
Result: negative

Test Type: in vivo assay

Species: Mouse

Cell type: Bone marrow

Result: negative

Germ cell mutagenicity - Assessment : Weight of evidence does not support classification as a germ cell mutagen.

**Carcinogenicity**

Not classified based on available information.

**Components:****Cellulose:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 72 weeks  
Result : negative

## Losartan / Hydrochlorothiazide Formulation

Version 5.4      Revision Date: 16.10.2020      SDS Number: 17073-00016      Date of last issue: 23.03.2020  
Date of first issue: 30.09.2014

---

**Losartan:**

Species : Mouse  
Application Route : Oral  
Exposure time : 92 weeks  
Dose : 200 mg/kg body weight  
Result : negative

Species : Rat  
Application Route : Oral  
Exposure time : 105 weeks  
Dose : 270 mg/kg body weight  
Result : negative

**Hydrochlorothiazide:**

Species : Mouse, female  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

Species : Mouse, male  
Application Route : Oral  
Exposure time : 2 Years  
Result : equivocal

Species : Rat, male and female  
Application Route : Oral  
Exposure time : 2 Years  
Result : negative

**Reproductive toxicity**

May damage the unborn child.  
May cause harm to breast-fed children.

**Components:****Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on fetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

**Losartan:**

Effects on fertility : Test Type: Fertility  
Species: Rat, female  
Application Route: Oral  
Fertility: LOAEL: 200 mg/kg body weight  
Result: female reproductive effects  
Remarks: Maternal toxicity observed.

## Losartan / Hydrochlorothiazide Formulation

Version 5.4      Revision Date: 16.10.2020      SDS Number: 17073-00016      Date of last issue: 23.03.2020  
Date of first issue: 30.09.2014

---

Effects on fetal development : Test Type: Development  
Species: Rabbit  
Application Route: Oral  
General Toxicity Maternal: NOAEL: 10 mg/kg body weight  
Developmental Toxicity: NOAEL F1: 20 mg/kg body weight  
Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, No teratogenic effects.

Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: LOAEL: 10 mg/kg body weight  
Result: Fetotoxicity., No teratogenic effects.

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

Studies indicating a hazard to babies during the lactation period

**Hydrochlorothiazide:**

Effects on fertility : Test Type: Fertility  
Species: Rat, male and female  
Application Route: oral (feed)  
Fertility: NOAEL: 4 mg/kg body weight  
Result: Effects on fertility.

Test Type: Fertility  
Species: Mouse, male and female  
Application Route: oral (feed)  
Fertility: NOAEL: 100 mg/kg body weight  
Result: Effects on fertility.

Effects on fetal development : Test Type: Development  
Species: Mouse  
Application Route: Oral  
Developmental Toxicity: NOAEL: 3,000 mg/kg body weight  
Result: No teratogenic effects.

Test Type: Development  
Species: Rat  
Application Route: Oral  
Developmental Toxicity: NOAEL: 1,000 mg/kg body weight  
Result: No teratogenic effects.

**STOT-single exposure**

Not classified based on available information.

**STOT-repeated exposure**

Causes damage to organs (Kidney, Parathyroid gland) through prolonged or repeated exposure.  
May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

## Losartan / Hydrochlorothiazide Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 23.03.2020  |
| 5.4     | 16.10.2020     | 17073-00016 | Date of first issue: 30.09.2014 |

---

**Components:****Losartan:**

|                    |   |  |
|--------------------|---|--|
| Routes of exposure | : | Ingestion  |
| Target Organs      | : | Blood, Cardio-vascular system, Stomach, Kidney                     |
| Assessment         | : | May cause damage to organs through prolonged or repeated exposure. |

**Hydrochlorothiazide:**

|               |   |   |
|---------------|---|---|
| Target Organs | : | Kidney, Parathyroid gland                                       |
| Assessment    | : | Causes damage to organs through prolonged or repeated exposure. |

**Repeated dose toxicity****Components:****Cellulose:**

|                   |   |                |
|-------------------|---|----------------|
| Species           | : | Rat            |
| NOAEL             | : | >= 9,000 mg/kg |
| Application Route | : | Ingestion      |
| Exposure time     | : | 90 Days        |

**Losartan:**

|                     |   |  |
|---------------------|---|--|
| Species             | : | Rat  |
| LOAEL               | : | 15 mg/kg                                       |
| Application Route   | : | Oral   |
| Exposure time       | : | 309 d  |
| Number of exposures | : | daily  |
| Target Organs       | : | Blood, Kidney, Cardio-vascular system, Stomach |

|                   |   |                      |
|-------------------|---|----------------------|
| Species           | : | Dog                  |
| NOAEL             | : | 5 mg/kg              |
| Application Route | : | Oral                 |
| Exposure time     | : | 1 Months             |
| Symptoms          | : | Salivation, Vomiting |

|                     |   |                      |
|---------------------|---|----------------------|
| Species             | : | Dog                  |
| LOAEL               | : | 25 mg/kg             |
| Application Route   | : | Oral                 |
| Exposure time       | : | 53 Weeks             |
| Number of exposures | : | daily                |
| Symptoms            | : | Salivation, Vomiting |

**Starch:**

|                   |   |                         |
|-------------------|---|-------------------------|
| Species           | : | Rat                     |
| NOAEL             | : | >= 2,000 mg/kg          |
| Application Route | : | Skin contact            |
| Exposure time     | : | 28 Days                 |
| Method            | : | OECD Test Guideline 410 |

## Losartan / Hydrochlorothiazide Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 23.03.2020  |
| 5.4     | 16.10.2020     | 17073-00016 | Date of first issue: 30.09.2014 |

---

**Hydrochlorothiazide:**

Species : Rat, male and female  
 LOAEL : 10 mg/kg  
 Application Route : Oral  
 Exposure time : 2 y  
 Target Organs : Kidney, Parathyroid gland

Species : Mouse, male and female  
 NOAEL : 300 - 550 mg/kg  
 Application Route : Oral  
 Exposure time : 2 y  
 Remarks : No significant adverse effects were reported

Species : Dog  
 : 50 - 200 mg/kg  
 Application Route : Oral  
 Exposure time : 9 Months  
 Target Organs : Parathyroid gland

**Aspiration toxicity**

Not classified based on available information.

**Components:****Losartan:**

No aspiration toxicity classification

**Hydrochlorothiazide:**

No aspiration toxicity classification

**Experience with human exposure****Components:****Losartan:**

Eye contact : Symptoms: Eye irritation  
 Ingestion : Symptoms: hypotension, tachycardia

**Hydrochlorothiazide:**

Eye contact : Symptoms: Eye irritation  
 Ingestion : Symptoms: Dizziness, Headache, Fatigue, Nausea, Abdominal pain, hypotension, dry mouth, electrolyte imbalance, eye pain

**SECTION 12. ECOLOGICAL INFORMATION****Ecotoxicity****Components:****Cellulose:**

Toxicity to fish : LC50 (Oryzias latipes (Japanese medaka)): > 100 mg/l  
 Exposure time: 48 h

## Losartan / Hydrochlorothiazide Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 23.03.2020  |
| 5.4     | 16.10.2020     | 17073-00016 | Date of first issue: 30.09.2014 |

---

Remarks: Based on data from similar materials

**Losartan:**

- Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 929 mg/l  
Exposure time: 96 h  
Method: FDA 4.11
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 331 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202
- Toxicity to algae/aquatic plants : NOEC (Microcystis aeruginosa (blue-green algae)): 949 mg/l  
Exposure time: 10 d  
Method: FDA 4.01
- NOEC (Selenastrum capricornutum (green algae)): 143 mg/l  
Exposure time: 10 d  
Method: FDA 4.01
- Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 10 mg/l  
Exposure time: 32 d  
Method: OECD Test Guideline 210
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 100 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

**Hydrochlorothiazide:**

- Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): > 500 mg/l  
Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 500 mg/l  
Exposure time: 48 h

**Persistence and degradability****Components:****Cellulose:**

- Biodegradability : Result: Readily biodegradable.

**Losartan:**

- Stability in water : Hydrolysis: < 10 %(5 d)

**Hydrochlorothiazide:**

- Stability in water : Hydrolysis: 46.2 %(96 h)

**Bioaccumulative potential****Components:****Losartan:**

# SAFETY DATA SHEET



## Losartan / Hydrochlorothiazide Formulation



Version 5.4      Revision Date: 16.10.2020      SDS Number: 17073-00016      Date of last issue: 23.03.2020  
Date of first issue: 30.09.2014

---

Partition coefficient: n-octanol/water : log Pow: 1.2

### Mobility in soil

No data available

### Other adverse effects

No data available

---

## SECTION 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

## SECTION 14. TRANSPORT INFORMATION

### International Regulations

#### UNRTDG

Not regulated as a dangerous good

#### IATA-DGR

Not regulated as a dangerous good

#### IMDG-Code

Not regulated as a dangerous good

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### Domestic regulation

#### NOM-002-SCT

Not regulated as a dangerous good

### Special precautions for user

Not applicable

---

## SECTION 15. REGULATORY INFORMATION

### Safety, health and environmental regulations/legislation specific for the substance or mixture

Federal Law for the control of chemical precursors, essential chemical products and machinery for producing capsules, tablets and pills. : Not applicable

### The ingredients of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

---



## Losartan / Hydrochlorothiazide Formulation

|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 23.03.2020  |
| 5.4     | 16.10.2020     | 17073-00016 | Date of first issue: 30.09.2014 |

---

**SECTION 16. OTHER INFORMATION****Full text of other abbreviations**

ACGIH : USA. ACGIH Threshold Limit Values (TLV)  
 NOM-010-STPS-2014 : Mexico. Norm NOM-010-STPS-2014 on Chemicals Polluting the Work Environment - Identification, Assessment and Control - Appendix 1 Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average  
 NOM-010-STPS-2014 / VLE- : Time weighted average limit value  
 PPT

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Revision Date : 16.10.2020

# SAFETY DATA SHEET



## Losartan / Hydrochlorothiazide Formulation



|         |                |             |                                 |
|---------|----------------|-------------|---------------------------------|
| Version | Revision Date: | SDS Number: | Date of last issue: 23.03.2020  |
| 5.4     | 16.10.2020     | 17073-00016 | Date of first issue: 30.09.2014 |

---

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8